National Cancer Institute (NCI): all 3,554 studies

Page 6 of 36. Open to participants first (334), then studies with results posted, then the rest; newest registration first within each.

• M7824 in People With Recurrent Respiratory PapillomatosisCompletedNCT03707587Phase 2Results posted
• Daunorubicin and Cytarabine With or Without Uproleselan in Treating Older Adult Patients With Acute Myeloid Leukemia Receiving Intensive Induction ChemotherapyActive, not recruitingNCT03701308Phase 2/3Results posted
• Pinometostat and Azacitidine in Treating Patients With Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia With 11q23 RearrangementCompletedNCT03701295Phase 1/2Results posted
• Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)Active, not recruitingNCT03698994Phase 2Results posted
• A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk MelanomaActive, not recruitingNCT03698019Phase 2Results posted
• Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or DysregulationActive, not recruitingNCT03663933Phase 2Results posted
• Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib AloneActive, not recruitingNCT03660826Phase 2Results posted
• Confocal Endoscopic Microscopy for Detection of Early Stage Gastric Cancer in Subjects With Hereditary Diffuse Gastric Cancer SyndromeCompletedNCT03648879Phase 2Results posted
• Anti-Mesothelin Immunotoxin LMB-100 Followed by Pembrolizumab in Malignant MesotheliomaTerminatedNCT03644550Phase 2Results posted
• Sunitinib in Sarcomas of the Central Nervous SystemTerminatedNCT03641326Phase 2Results posted
• Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction CancerCompletedNCT03641313Phase 2Results posted
• T Cells Expressing a Novel Fully-Human Anti-BCMA CAR for Treating Multiple MyelomaCompletedNCT03602612Phase 1Results posted
• Testing Whether the Combination of Two Immunotherapy Drugs Have Activity in Recurrent or Persistent Clear Cell Ovarian CancerCompletedNCT03602586Phase 2Results posted
• Atezolizumab and Cobimetinib in Treating Patients With Metastatic, Recurrent, or Refractory Non-small Cell Lung CancerActive, not recruitingNCT03600701Phase 2Results posted
• Savolitinib in Treating Patients With Recurrent or Refractory Primary CNS TumorsActive, not recruitingNCT03598244Phase 1Results posted
• A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC)Active, not recruitingNCT03595124Phase 2Results posted
• Savolitinib in Treating Patients With MET Amplified Metastatic or Unresectable Colorectal CancerTerminatedNCT03592641Phase 2Results posted
• M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung CancersCompletedNCT03554473Phase 1/2Results posted
• Feasibility and Preliminary Efficacy of a Mindfulness-based Intervention for Children and Young Adults With High Grade or High-Risk Cancer and Their CaregiversCompletedNCT03538587Not applicableResults posted
• Olaparib in People With Malignant MesotheliomaCompletedNCT03531840Phase 2Results posted
• Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide TreatmentTerminatedNCT03531827Phase 2Results posted
• Medication Adherence in Children, Adolescents and Adults With Neurofibromatosis Type 1(NF1) on Clinical Treatment TrialsCompletedNCT03531814Not applicableResults posted
• Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)CompletedNCT03526250Phase 2Results posted
• M6620 and Carboplatin With or Without Docetaxel in Treating Patients With Metastatic Castration-Resistant Prostate CancerActive, not recruitingNCT03517969Phase 2Results posted
• Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial CarcinomaCompletedNCT03513952Phase 2Results posted
• Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1)CompletedNCT03493945Phase 1/2Results posted
• Copanlisib Hydrochloride and Nivolumab in Treating Patients With Recurrent or Refractory Diffuse Large B-cell Lymphoma or Primary Mediastinal Large B-cell LymphomaCompletedNCT03484819Phase 2Results posted
• Treatment of Castration Resistant Prostate Cancer Using Multi-Targeted Recombinant Ad5 PSA/MUC1/Brachyury Based Immunotherapy VaccinesCompletedNCT03481816Phase 1Results posted
• Messenger RNA (mRNA)-Based, Personalized Cancer Vaccine Against Neoantigens Expressed by the Autologous CancerTerminatedNCT03480152Phase 1/2Results posted
• Study to Compare Capsule and Liquid Formulations of Enzalutamide After Single Dose Administration Under Fasting Conditions in Prostate CancerTerminatedNCT03478904Phase 1Results posted
• Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung CancerCompletedNCT03468985Phase 2Results posted
• M7824 (MSB0011359C) in Combination With Gemcitabine in Adults With Previously Treated Advanced Adenocarcinoma of the PancreasTerminatedNCT03451773Phase 1/2Results posted
• CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell MalignanciesCompletedNCT03448393Phase 1Results posted
• The Effects of Castration on the Pharmacokinetics of Zolpidem After Single Dose Administration In Men With Prostate Cancer Undergoing Androgen Deprivation Therapy Compared to Normal Healthy FemalesTerminatedNCT03436745Phase 1Results posted
• Mesothelin-Targeted Immunotoxin LMB-100 in Combination With SEL-110 in Subjects With Malignant Pleural or Peritoneal MesotheliomaTerminatedNCT03436732Phase 1Results posted
• M7824 in Subjects With HPV Associated MalignanciesCompletedNCT03427411Phase 2Results posted
• Broccoli Sprout/Broccoli Seed Extract Supplement in Decreasing Toxicity in Heavy SmokersCompletedNCT03402230Early Phase 1Results posted
• ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial CarcinomaCompletedNCT03394027Phase 2Results posted
• Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory CancersCompletedNCT03388632Phase 1Results posted
• Highly Conformal, Hypofractionated, Focally Dose Escalated Post-Prostatectomy RadiotherapyCompletedNCT03388619Phase 1Results posted
• Multi-Targeted Recombinant Ad5 (CEA/MUC1/Brachyury) Based Immunotherapy Vaccine Regimen in People With Advanced CancerCompletedNCT03384316Phase 1Results posted
• Pilot Study of Denosumab in BRCA1/2 Mutation Carriers Scheduled for Risk-Reducing Salpingo-OophorectomyTerminatedNCT03382574Early Phase 1Results posted
• Cisplatin/Carboplatin and Etoposide With or Without Nivolumab in Treating Patients With Extensive Stage Small Cell Lung CancerCompletedNCT03382561Phase 2Results posted
• Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid TumorsActive, not recruitingNCT03375320Phase 3Results posted
• Cabozantinib S-malate and Nivolumab in Treating Patients With Advanced, Recurrent, or Metastatic Endometrial CancerActive, not recruitingNCT03367741Phase 2Results posted
• Hepatic Artery Infusion Pump Chemotherapy With Floxuridine and Dexamethasone in Combination With Systemic Chemotherapy for Patients With Colorectal Cancer Metastatic to the LiverCompletedNCT03366155Phase 2Results posted
• Navitoclax and Vistusertib in Treating Patients With Relapsed Small Cell Lung Cancer and Other Solid TumorsTerminatedNCT03366103Phase 1/2Results posted
• Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial CancerActive, not recruitingNCT03348631Phase 2Results posted
• Testing AZD1775 inC Combination With Radiotherapy and Chemotherapy in Cervical, Upper Vaginal and Uterine CancersTerminatedNCT03345784Phase 1Results posted
• Bexarotene in Preventing Breast Cancer in Patients at High Risk for Breast CancerCompletedNCT03323658Phase 1Results posted
• Phase I Trial of Endoxifen Gel Versus Placebo in Women Undergoing Breast SurgeryActive, not recruitingNCT03317405Phase 1Results posted
• Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone MetastasisActive, not recruitingNCT03317392Phase 1/2Results posted
• Combination Immunotherapy in Biochemically Recurrent Prostate CancerCompletedNCT03315871Phase 2Results posted
• Mogamulizumab and Pembrolizumab in Treating Patients With Relapsed or Refractory Diffuse Large B Cell LymphomaCompletedNCT03309878Phase 1/2Results posted
• Testing the Addition of Radiation Therapy to Immunotherapy for Merkel Cell CarcinomaCompletedNCT03304639Phase 2Results posted
• Ability of a Dendritic Cell Vaccine to Immunize Melanoma or Epithelial Cancer Patients Against Defined Mutated Neoantigens Expressed by the Autologous CancerTerminatedNCT03300843Phase 2Results posted
• MUC1 Vaccine in Preventing Lung Cancer in Current and Former Smokers at High Risk for Lung CancerActive, not recruitingNCT03300817Phase 1Results posted
• Dolcanatide in Preventing Colorectal Cancer in Healthy VolunteersCompletedNCT03300570Phase 1Results posted
• Exemestane in Treating Patients With Complex Atypical Hyperplasia of the Endometrium/Endometrial Intraepithelial Neoplasia or Low Grade Endometrial CancerCompletedNCT03300557Phase 2Results posted
• Talimogene Laherparepvec, Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Locally Advanced or Metastatic Rectal CancerTerminatedNCT03300544Phase 1Results posted
• Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic LeukemiaActive, not recruitingNCT03289910Phase 2Results posted
• Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)CompletedNCT03258593Phase 1Results posted
• Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take CisplatinCompletedNCT03258554Phase 2/3Results posted
• Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma (PCNSL), and Other Extranodal Diffuse Large B-cell LymphomasCompletedNCT03255018Phase 2Results posted
• Prostate SBRT for Locally Recurrent Prostate Cancer After Prior RadiotherapyCompletedNCT03253744Phase 1Results posted
• AZD1775 in Treating Patients With Advanced Refractory Solid Tumors With CCNE1 AmplificationCompletedNCT03253679Phase 2Results posted
• Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal CarcinomasTerminatedNCT03233724Phase 1/2Results posted
• Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)CompletedNCT03233204Phase 2Results posted
• Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant MesotheliomaActive, not recruitingNCT03228537Phase 1Results posted
• Metabolomic and BH3 Profiling of Esophageal Cancers: Identification of Novel Assessment Methods of Treatment Response for Precision TherapyTerminatedNCT03223662Phase 2Results posted
• Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)CompletedNCT03220035Phase 2Results posted
• Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell LymphomasActive, not recruitingNCT03220022Phase 1Results posted
• PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by SurgeryCompletedNCT03218826Phase 1Results posted
• Navtemadlin and Radiation Therapy in Treating Patients With Soft Tissue SarcomaCompletedNCT03217266Phase 1Results posted
• Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)Active, not recruitingNCT03213704Phase 2Results posted
• Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)CompletedNCT03213691Phase 2Results posted
• Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)CompletedNCT03213678Phase 2Results posted
• Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)CompletedNCT03213665Phase 2Results posted
• Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)Active, not recruitingNCT03213652Phase 2Results posted
• Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 MutationsActive, not recruitingNCT03212274Phase 2Results posted
• Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)Active, not recruitingNCT03210714Phase 2Results posted
• A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal CancerCompletedNCT03206073Phase 1/2Results posted
• Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal CancerTerminatedNCT03206047Phase 1/2Results posted
• Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder CancerCompletedNCT03201458Phase 2Results posted
• Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast CancerTerminatedNCT03199885Phase 3Results posted
• Immunotherapy With E6 T Cell Receptor (TCR) T Cells for Vulvar High-Grade Squamous Intraepithelial LesionsTerminatedNCT03197025Phase 1Results posted
• Topical Fluorouracil and Imiquimod in Treating Patients With High-Grade Cervical Intraepithelial NeoplasiaCompletedNCT03196180Early Phase 1Results posted
• T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic RadiosurgeryTerminatedNCT03190967Phase 1/2Results posted
• Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic LeukemiaActive, not recruitingNCT03190915Phase 2Results posted
• Immune Checkpoint Inhibitor Nivolumab in People With Recurrent Select Rare CNS CancersTerminatedNCT03173950Phase 2Results posted
• A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney CancerTerminatedNCT03165721Phase 2Results posted
• Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)Active, not recruitingNCT03155620Phase 2Results posted
• Trametinib in Treating Patients With Epithelioid Hemangioendothelioma That is Metastatic, Locally Advanced, or Cannot Be Removed by SurgeryCompletedNCT03148275Phase 2Results posted
• Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural MesotheliomaActive, not recruitingNCT03126630Phase 1/2Results posted
• Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC)CompletedNCT03111732Phase 2Results posted
• Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeCompletedNCT03092674Phase 2/3Results posted
• Heated Intraperitoneal Chemotherapy and Gastrectomy for Gastric Cancer With Positive Peritoneal CytologyCompletedNCT03092518Phase 2Results posted
• Pembrolizumab in Recurrent or Metastatic Medullary Thyroid CancerCompletedNCT03072160Phase 2Results posted
• Testing the Combination of Two Experimental Drugs MK-3475 (Pembrolizumab) and Interferon-gamma for the Treatment of Mycosis Fungoides and Sézary Syndrome and Advanced Synovial SarcomaCompletedNCT03063632Phase 2Results posted
• Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing NephrectomyActive, not recruitingNCT03055013Phase 3Results posted

← National Cancer Institute (NCI) overview and focus areas